A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
NCT06897475
Recruiting
The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/01/2025
Locations: Helios Clinical Research - Phoenix, Phoenix, Arizona +55 locations
Conditions: Type 2 Diabetes
Register for Updates
Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)
NCT05396833
Recruiting
This is an open-label, multicenter, clinical study conducted in multiple parts to establish the safety, tolerability, Pharmacokinetic/Pharmacodynamic (PK/PD) profile, maximum tolerated dose (MTD) combinations (if observed) and recommended dose for expansion (RDE) combination for tuvusertib in combination with lartesertib (in Part A1), food effect on the PK of lartesertib as monotherapy followed by treatment with tuvusertib in combination with lartesertib in participants with specific tumor types... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Providence Medical Foundation, Santa Rosa, California +19 locations
Conditions: Metastatic or Locally Advanced Unresectable Solid Tumors
Register for Updates
BoStOn SCientific Rhythm MAnagemenT REgiStry (SOCRATES)
NCT04823663
Recruiting
SOCRATES is part of Boston Scientific's (BSC) Post-market surveillance system. The implementation of such systems is mandatory per local regulations such as the Regulation '(EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices' or short Medical Device Regulation (MDR). The SOCRATES design is therefore based on the BSC's commitment as well as external regulatory requirements to proactively and systematically gather, record and analyze relevant data on the... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/01/2025
Locations: Universitair Ziekenhuis Brussel, Jette, Not set +23 locations
Conditions: Cardiac Disease
Register for Updates
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
NCT05797805
Recruiting
This study will be conducted in 2 parts. The first part is a phase 1 single-agent dose escalation, and dose optimization, study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic therapy. The second part of the study will begin with a brief dose escalation part for each combination (tegavivint plus cabozantinib or tegavivint plus lenvatinib) followed by a combination dose expansion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: City of Hope, Duarte, California +7 locations
Conditions: Advanced Hepatocellular Carcinoma
Register for Updates
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626
Recruiting
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main quest... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Mayo Clinic - Phoenix, Phoenix, Arizona +173 locations
Conditions: Metastatic Breast Cancer
Register for Updates
Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus
NCT06787586
Recruiting
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-1310 in healthy adults, patients with atopic dermatitis and patients with chronic pruritus. The main questions it aims to answer are: What medical problems do participants have when taking ATTO-1310? How long does ATTO-1310 stay in the body after dosing? Researchers will compare ATTO-1310 to a placebo (a look-alike substance that contains no drug). Participants will be dosed with ATTO-1310 or a... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/30/2025
Locations: Attovia Clinical Site 103, Encinitas, California +13 locations
Conditions: Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Chronic Pruritus
Register for Updates
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT06419634
Recruiting
The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 as a monotherapy, in double combination with Azacitidine and in triple combination with Azacitidine and Venetoclax in participants with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Yale-New Haven Hospital, New Haven, Connecticut +14 locations
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Register for Updates
Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma
NCT06319196
Recruiting
Clear-Me is a biomarker-driven phase II study that tests whether the combination anti- lymphocyte-activation gene-3 (LAG3)/anti-programmed cell death protein 1(PD-1) inhibition Bristol-Myers Squibb (BMS986213) is superior to anti-PD-1 inhibition in patients with detectable circulating tumor deoxyribonucleic acid (ctDNA) following definitive surgery for high risk melanoma. Patients will be allocated to either Arm A or Arm B via the process of randomization. The randomization process will be strat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: UHN- Princess Margaret Cancer Center, Toronto, Ontario
Conditions: Cutaneous Melanoma, Melanoma Stage IV, Mucosal Melanoma
Register for Updates
Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II
NCT06392009
Recruiting
Study RAD-GRIN-201 is a phase 1B/2A trial to assess safety, tolerability, pharmacokinetics (PK), and potential efficacy of radiprodil in participants with Tuberous Sclerosis Complex (TSC) or Focal Cortical Dysplasia (FCD) type II. The study is open-label, so all participants will be treated with radiprodil. Subjects' participation in the study is expected to last up to six months in Part A and one year in Part B/long-term treatment period. The treatment period in Part B may be extended based on... Read More
Gender:
ALL
Ages:
Between 6 months and 18 years
Trial Updated:
06/30/2025
Locations: Queensland Children Hospital, South Brisbane, Not set +19 locations
Conditions: Tuberous Sclerosis Complex, Focal Cortical Dysplasia
Register for Updates
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
NCT03040973
Recruiting
The purpose of this study is to assess long-term safety and provide continued study treatment access to eligible participants who are judged by the Investigator to benefit from continued treatment with capmatinib monotherapy or in combination with other treatments or with the combination treatment alone in a Novartis sponsored study
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/30/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts +16 locations
Conditions: Advanced Solid Tumors Which Are cMET-dependent
Register for Updates
TrialNet Pathway to Prevention of T1D
NCT00097292
Recruiting
Rationale: The accrual of data from the laboratory and from epidemiologic and prevention trials has improved the understanding of the etiology and pathogenesis of type 1 diabetes mellitus (T1DM). Genetic and immunologic factors play a key role in the development of T1DM, and characterization of the early metabolic abnormalities in T1DM is steadily increasing. However, information regarding the natural history of T1DM remains incomplete. The TrialNet Natural History Study of the Development of T... Read More
Gender:
ALL
Ages:
Between 2 years and 45 years
Trial Updated:
06/30/2025
Locations: Childrens Hospital of Orange County, Orange, California +21 locations
Conditions: Diabetes Mellitus, Type 1
Register for Updates
TOward a comPrehensive Supportive Care Intervention for Older Men With Metastatic Prostate Cancer
NCT05582772
Recruiting
TOPCOP3 is a pilot factorial RCT of geriatric assessment and management, remote symptom monitoring, both interventions or neither, accompanied by an embedded process evaluation. This design is widely used to guide the evaluation of complex interventions and provides important data to aid design of larger RCTs. The trial itself falls within pilot trial goals including obtaining variance estimates for outcomes, assessment of recruitment potential, and understanding implementation issues vital to d... Read More
Gender:
MALE
Ages:
65 years and above
Trial Updated:
06/30/2025
Locations: St. Michael's hospital, Toronto, Ontario +2 locations
Conditions: Metastatic Prostate Cancer
Register for Updates